XML 49 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Segment and Geographical Information (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Business Segment Information
(In millions)202120202019
Revenues
Life Sciences Solutions
$15,631 $12,168 $6,856 
Analytical Instruments
6,069 5,124 5,522 
Specialty Diagnostics
5,659 5,343 3,718 
Laboratory Products and Biopharma Services
14,862 12,245 10,599 
Eliminations
(3,010)(2,662)(1,153)
Consolidated revenues
39,211 32,218 25,542 
Segment Income
Life Sciences Solutions
7,817 6,109 2,446 
Analytical Instruments
1,197 808 1,273 
Specialty Diagnostics
1,280 1,368 930 
Laboratory Products and Biopharma Services
1,844 1,271 1,324 
Subtotal reportable segments
12,138 9,556 5,973 
Cost of revenues charges
(8)(6)(17)
Selling, general and administrative (charges) credits
(144)10 (62)
Restructuring and other (costs) income
(197)(99)413 
Amortization of acquisition-related intangible assets
(1,761)(1,667)(1,713)
Consolidated operating income
10,028 7,794 4,594 
Interest income43 65 224 
Interest expense(536)(553)(676)
Other income/(expense)
(694)(76)(70)
Income before income taxes
$8,841 $7,230 $4,072 
Depreciation
Life Sciences Solutions
$197 $140 $130 
Analytical Instruments
83 76 75 
Specialty Diagnostics
128 100 67 
Laboratory Products and Biopharma Services
423 342 292 
Consolidated depreciation
$831 $658 $564 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and accelerated depreciation on fixed assets to estimated disposal value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of third-party transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
(In millions)202120202019
Total assets
Life Sciences Solutions
$22,751 $20,209 $18,306 
Analytical Instruments
9,692 9,773 9,896 
Specialty Diagnostics
6,010 6,534 5,867 
Laboratory Products and Biopharma Services
52,639 22,711 21,761 
Corporate/other (a)
4,031 9,825 2,551 
Consolidated total assets
$95,123 $69,052 $58,381 
Capital expenditures
Life Sciences Solutions
$810 $392 $151 
Analytical Instruments
79 74 64 
Specialty Diagnostics
167 175 83 
Laboratory Products and Biopharma Services
1,327 772 554 
Corporate/other
140 61 74 
Consolidated capital expenditures
$2,523 $1,474 $926 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Business Segment Information
(In millions)202120202019
Revenues
Life Sciences Solutions
$15,631 $12,168 $6,856 
Analytical Instruments
6,069 5,124 5,522 
Specialty Diagnostics
5,659 5,343 3,718 
Laboratory Products and Biopharma Services
14,862 12,245 10,599 
Eliminations
(3,010)(2,662)(1,153)
Consolidated revenues
39,211 32,218 25,542 
Segment Income
Life Sciences Solutions
7,817 6,109 2,446 
Analytical Instruments
1,197 808 1,273 
Specialty Diagnostics
1,280 1,368 930 
Laboratory Products and Biopharma Services
1,844 1,271 1,324 
Subtotal reportable segments
12,138 9,556 5,973 
Cost of revenues charges
(8)(6)(17)
Selling, general and administrative (charges) credits
(144)10 (62)
Restructuring and other (costs) income
(197)(99)413 
Amortization of acquisition-related intangible assets
(1,761)(1,667)(1,713)
Consolidated operating income
10,028 7,794 4,594 
Interest income43 65 224 
Interest expense(536)(553)(676)
Other income/(expense)
(694)(76)(70)
Income before income taxes
$8,841 $7,230 $4,072 
Depreciation
Life Sciences Solutions
$197 $140 $130 
Analytical Instruments
83 76 75 
Specialty Diagnostics
128 100 67 
Laboratory Products and Biopharma Services
423 342 292 
Consolidated depreciation
$831 $658 $564 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and accelerated depreciation on fixed assets to estimated disposal value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of third-party transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Geographical Information
(In millions)202120202019
Revenues (b)
United States
$18,907 $16,435 $12,366 
China
3,444 2,797 2,752 
Other
16,860 12,986 10,424 
Consolidated revenues
$39,211 $32,218 $25,542 
Long-lived Assets (c)
United States
$5,578 $3,686 $3,099 
Other
4,286 3,001 2,349 
Consolidated long-lived assets
$9,864 $6,687 $5,448 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.